Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 15-Oct-24 4:22 PM View:  | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 14-Oct-24 | Option Exercise | 5,352 | $1.08 | $5,780.16 | 4% 130.62K to 135.97K | |
| 15-Oct-24 4:21 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 11-Oct-24 | Market Sale (Planned) | 15,271 | $13.52 | $206,433.00 | (2%) 911.21K to 895.94K | (5%) |
| 15-Oct-24 4:22 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Oct-24 | Option Exercise | 5,017 | $0.54 | $2,709.18 | 4% 125.61K to 130.62K | |
| 15-Oct-24 4:22 PM View: | Levy Adam Scott CFO and Secretary | Mineralys Therapeutics, Inc. (MLYS) | 11-Oct-24 | Market Sale (Planned) | 10,757 | $13.57 | $146,004.00 | (4%) 247.61K to 236.85K | (5%) |
| 12-Sep-24 4:32 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 12-Sep-24 | Option Exercise | 6,349 | $1.08 | $6,856.92 | 5% 119.26K to 125.61K | |
| 12-Sep-24 4:32 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Sep-24 | Option Exercise | 5,018 | $0.54 | $2,709.72 | 4% 114.24K to 119.26K | |
| 13-Aug-24 4:20 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 12-Aug-24 | Option Exercise | 11,365 | $0.84 | $9,565.02 | 11% 102.87K to 114.24K | |
| 26-Jul-24 9:45 PM View: | Slingsby Brian Taylor Director 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 24-Jul-24 | Market Sale | 550,000 | $13.05 | $7,177,500.00 | (6%) 9.19M to 8.64M | (9%) |
| 18-Jul-24 6:34 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 16-Jul-24 | Planned Option Sale | 525 | $15.00 | $7,875.58 | (< 1%) 103.4K to 102.87K | |
| 18-Jul-24 6:34 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 16-Jul-24 | Option Exercise | 525 | $1.08 | $567.00 | < 1% 102.87K to 103.4K | |
| 12-Jul-24 4:39 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 12-Jul-24 | Option Exercise | 6,349 | $1.08 | $6,856.92 | 7% 96.52K to 102.87K | |
| 12-Jul-24 4:37 PM View: | Levy Adam Scott CFO and Secretary | Mineralys Therapeutics, Inc. (MLYS) | 11-Jul-24 | Market Sale (Planned) | 10,757 | $13.14 | $141,394.00 | (4%) 258.37K to 247.61K | (8%) |
| 12-Jul-24 4:36 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 11-Jul-24 | Market Sale (Planned) | 15,746 | $13.34 | $210,075.00 | (2%) 926.96K to 911.21K | (6%) |
| 12-Jul-24 4:39 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Jul-24 | Option Exercise | 5,017 | $0.54 | $2,709.18 | 5% 91.51K to 96.52K | |
| 20-Jun-24 5:44 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 20-Jun-24 | Sale (Planned) | 14,940 | $11.73 | $175,237.00 | (2%) 941.9K to 926.96K | |
| 20-Jun-24 5:44 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 18-Jun-24 | Market Sale (Planned) | 16,607 | $11.99 | $199,073.00 | (2%) 958.5K to 941.9K | (18%) |
| 20-Jun-24 5:44 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 17-Jun-24 | Market Sale (Planned) | 17,766 | $12.25 | $217,712.00 | (2%) 976.27K to 958.5K | (16%) |
| 14-Jun-24 6:15 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 14-Jun-24 | Market Sale (Planned) | 16,229 | $12.52 | $203,163.00 | (2%) 992.5K to 976.27K | (13%) |
| 14-Jun-24 6:15 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 13-Jun-24 | Market Sale (Planned) | 39,961 | $12.74 | $509,027.00 | (4%) 1.03M to 992.5K | (11%) |
| 13-Jun-24 5:32 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 12-Jun-24 | Option Exercise | 6,349 | $1.08 | $6,856.92 | 8% 83.38K to 89.73K | |
| 14-Jun-24 6:15 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 12-Jun-24 | Market Sale (Planned) | 16,607 | $12.77 | $212,013.00 | (2%) 1.05M to 1.03M | (11%) |
| 13-Jun-24 5:32 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Jun-24 | Option Exercise | 5,017 | $0.54 | $2,709.18 | 6% 78.36K to 83.38K | |
| 13-Jun-24 5:33 PM View: | Levy Adam Scott CFO and Secretary | Mineralys Therapeutics, Inc. (MLYS) | 11-Jun-24 | Market Sale (Planned) | 96,815 | $12.94 | $1,252,720.00 | (27%) 352.28K to 255.46K | (10%) |
| 15-May-24 4:43 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 13-May-24 | Option Exercise | 11,366 | $0.84 | $9,565.56 | 17% 67.0K to 78.36K | |
| 10-May-24 4:17 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 09-May-24 | Option Exercise | 100 | $1.08 | $108.00 | < 1% 67.0K to 67.1K | |
| 10-May-24 4:17 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 09-May-24 | Planned Option Sale | 100 | $15.00 | $1,500.00 | (< 1%) 67.1K to 67.0K | |
| 15-Apr-24 4:24 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 12-Apr-24 | Option Exercise | 6,349 | $1.08 | $6,856.92 | 10% 60.65K to 67.0K | |
| 15-Apr-24 4:24 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Apr-24 | Option Exercise | 5,017 | $0.54 | $2,709.18 | 9% 55.63K to 60.65K | |
| 13-Mar-24 5:35 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 12-Mar-24 | Option Exercise | 6,348 | $1.08 | $6,855.84 | 13% 49.28K to 55.63K | |
| 13-Mar-24 5:35 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Mar-24 | Option Exercise | 5,017 | $0.54 | $2,709.18 | 11% 44.27K to 49.28K | |
| 14-Feb-24 9:07 PM View: | Akkaraju Srinivas Director 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 12-Feb-24 | Grant | 555,555 | $13.50 | $7,499,990.00 | 12% 4.52M to 5.07M | 5% |
| 14-Feb-24 7:49 PM View: | Ra Capital Management, LLC Director | Mineralys Therapeutics, Inc. (MLYS) | 12-Feb-24 | Grant | 1,672,510 | $13.50 | $22,578,900.00 | 53% 3.18M to 4.85M | 5% |
| 14-Feb-24 9:06 PM View: | Samsara Biocapital Gp, LLC 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 12-Feb-24 | Market Purchase | 555,555 | $13.50 | $7,499,990.00 | 12% 4.52M to 5.07M | 5% |
| 13-Feb-24 4:08 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 12-Feb-24 | Option Exercise | 11,366 | $0.84 | $9,566.10 | 35% 32.9K to 44.27K | |
| 12-Jan-24 4:01 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 12-Jan-24 | Option Exercise | 6,348 | $1.08 | $6,855.84 | 24% 26.55K to 32.9K | |
| 12-Jan-24 4:01 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Jan-24 | Option Exercise | 5,017 | $0.54 | $2,709.18 | 23% 21.54K to 26.55K | |
| 12-Dec-23 5:08 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Dec-23 | Option Exercise | 5,018 | $0.54 | $2,709.72 | 33% 15.05K to 20.07K | |
| 27-Nov-23 4:01 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 22-Nov-23 | Private Purchase | 4,250 | $5.97 | $25,355.90 | < 1% 1.04M to 1.05M | |
| 14-Nov-23 6:18 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 13-Nov-23 | Option Exercise | 5,017 | $0.54 | $2,709.18 | 50% 10.03K to 15.05K | |
| 07-Nov-23 5:15 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 03-Nov-23 | Option Exercise | 10,034 | $0.54 | $5,418.36 | 100% 0 to 10.03K | |
| 08-Sep-23 8:49 AM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 06-Sep-23 | Private Purchase | 2,250 | $12.08 | $27,180.00 | < 1% 1.04M to 1.04M | |
| 21-Aug-23 4:03 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 17-Aug-23 | Private Purchase | 2,250 | $12.10 | $27,225.00 | < 1% 1.04M to 1.04M | |
| 11-Aug-23 7:11 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 11-Aug-23 | Market Purchase | 2,000 | $12.89 | $25,780.00 | < 1% 1.04M to 1.04M | 10% |
| 11-Aug-23 7:11 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Aug-23 | Option Exercise | 157,091 | $0.80 | $125,967.00 | 100% 0 to 157.09K | |
| 11-Aug-23 7:11 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Aug-23 | Option Sale | 157,091 | $12.81 | $2,012,340.00 | (100%) 157.09K to 0 | |
| 11-Aug-23 7:11 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 10-Aug-23 | Option Exercise | 74,625 | $0.54 | $40,297.50 | 100% 0 to 74.63K | |
| 11-Aug-23 7:11 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 10-Aug-23 | Option Sale | 74,625 | $13.16 | $982,065.00 | (100%) 74.63K to 0 | |
| 16-Feb-23 4:54 PM View: | Akkaraju Srinivas Director 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 14-Feb-23 | Conversion | 3,581,860 | -- | -- | 100% 0 to 3.58M | |
| 16-Feb-23 4:54 PM View: | Slingsby Brian Taylor Director 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 14-Feb-23 | Conversion | 4,314,090 | -- | -- | 93% 4.63M to 8.94M | |
| 16-Feb-23 5:04 PM View: | Ra Capital Management, LLC Director | Mineralys Therapeutics, Inc. (MLYS) | 14-Feb-23 | Conversion | 1,928,480 | -- | -- | 100% 0 to 1.93M |
